GlobeNewswire by notified

RCI Banque : RCI Banque discloses exposure to Russia and Ukraine

Share

April, 1st 2022

RCI Banque discloses exposure to Russia and Ukraine

RCI Banque has investments and operations in Russia and Ukraine. The bank strictly complies with the regulations in force and diligently implements the necessary measures to comply with international sanctions as soon as they are published.

Given the way the bank operates in these two countries, balance sheet exposure to Russia and Ukraine is limited.

Russia:

RCI Banque main exposure to Russia derives from its equity investment in RN Bank, a self-funded Joint Venture in which we hold 30% of the economic interest and that we consolidate by the equity method. RCI Banque share of RN Bank equity was 92 M€ as of 31/12/2021.

RCI Banque is assessing the available options with RN Bank other shareholders, taking into account the current environment, while acting responsibly towards RN Bank employees.

RCI Banque also owns 100 % of RNL Leasing, a small leasing company that we consolidate by global integration. As of 31/12/2021, RCI Banque equity investment in RNL Leasing was 2 M€ while intra-group loans amounted to 15 M€.

A non-cash adjustment may have to be recorded against the book value of our assets in Russia at the time of the 2022 first half results. As of December 31, 2021, this value amounted to 109 million euros representing approximatively 22bps1 of RCI Banque's 2021-year end CET1 ratio (14.76%). Our strong capital position would allow us to absorb such adverse shock.

Ukraine:

In Ukraine we have a commercial agreement carried out by a non-consolidated subsidiary and therefore no lending exposure. RCI Banque’s net investment is limited to the equity share of this subsidiary (0,3 M€).

We continue to dynamically monitor our risk exposure, whilst constantly assessing the potential impact of the conflict.

Contacts



Analysts and Investors



Financial Communication
+ 33(0) 1 76 88 81 74
contact_investor@rcibanque.com

About RCI Bank and Services:
As a partner caring for all its customers, RCI Bank and Services builds innovative financial services to create sustainable mobility for all. A subsidiary of the Renault Group created almost 100 years ago, RCI Bank and Services is a French Bank specializing in automotive financing and services for Alliance customers and networks.
With operations in 36 countries and nearly 4,000 employees, the group financed over 1.4 million contracts (new and used vehicles) in 2021 and sold 4.7 million services.
At end 2021, average performing assets stood at €44.8 billion in financing and pre-tax income at 1,194 million.
Since 2012, RCI Bank and Services has rolled out a deposits collection business in several countries. At the end of December 2021, net deposits collected totaled €21 billion or 47% of the company's net assets.

To find out more about RCI Bank and Services: www.rcibs.com

Follow us on Twitter: @RCIBS


1 Impact on CET 1 ratio:

In €M31/12/2021After adjustmentImpact
CET1 capital 4 9324 823-109 (1)
Risk-weighted exposure amount33 42033 174-246 (2)
Common Equity Tier 1 ratio (%)14,76%14,54%- 22 bps
(1) In case of full depreciation of RN Bank equity (€92M), RNL Leasing equity (€2M) and loans to RNL Leasing (€15M)
(2) Decrease of RWA linked to equity investments in RN Bank (€92M with 250 % risk weight), depreciation on RNL Leasing Risk-Weighted assets (€16M)

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Joint Press Release – Kalera and Agrico Announce Effectiveness of Registration Statement, Waiver of Minimum Cash Condition and Extraordinary General Meetings for Proposed Business Combination16.5.2022 08:00:00 CEST | Press release

Extraordinary general meeting of Kalera shareholders (the “Kalera Special Meeting”) and extraordinary general meeting of Agrico shareholders (the “Agrico Special Meeting” and, together with the Kalera Special Meeting, the “Special Meetings”) to approve the proposed business combination of Kalera and Agrico expected to be held on June 27, 2022. Record date for the Kalera Special Meeting is June 6, 2022 (the “Kalera Record Date”); Record date for the Agrico Special Meeting is May 12, 2022 (the “Agrico Record Date” and, together with the Kalera Record Date, the “Record Dates”).Kalera shareholders as of June 6, 2022 voting by proxy should submit their vote by June 22, 2022.Agrico shareholders as of May 12, 2022 voting by proxy should submit their vote by 10:00 a.m., Eastern Time on June 25, 2022.Kalera has waived the minimum cash closing condition. Despite the waiver of the condition, if the minimum cash condition is not satisfied upon the consummation of the business combination, Agrico’s

Inventiva secures a €50 million credit facility from the European Investment Bank16.5.2022 08:00:00 CEST | Press release

This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a €50 million bullet credit facility agreement with the European Investment Bank (“EIB”). The Company plans to use the facility toward its preclinical and clinical pipeline, including to help fund a portion of its Phase III clinical trial of lan

Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling16.5.2022 08:00:00 CEST | Pressemelding

Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd, minst 10-faldig, minskning av MRD efter behandling med DCP-001Efter en medianuppföljningsperiod på 14,3 månader har medianen för återfallsfri överlevnad (RFS) och total överlevnad (OS) ännu inte uppnåtts.Estimerad RFS vid 6 månader baserad på för närvarande tillgänglig data är 83,7% och estimerad 6-månaders OS är 97,0%Immunicum planerar att presentera fler uppdateringar av överlevnadsdata, inklusive RFS och OS, samt immunövervakningsdata under Q4 2022Företaget håller konferenssamtal och webbsändning i dag kl. 14:00 CET (8:00am ET, 1.00pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag uppdaterade interimsresultat från det pågående ADVANCE II kliniska test som utvärder

Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment16.5.2022 08:00:00 CEST | Press release

Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001After a median follow-up period of 14.3 months, median relapse-free survival (RFS) and overall survival (OS) have not yet been reachedThe estimated 6-month RFS based on the currently available data is 83.7% and the estimated 6-month OS is 97.0%Immunicum plans to present further updates on survival data including RFS and OS, as well as immunomonitoring data in Q4 2022Company to host conference call and webcast today at 14:00 CET (8am ET, 1pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced today updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead developmen

Energy partnership agreement between Vantaa Energy and SATO supports the achievement of SATO’s carbon neutrality target16.5.2022 08:00:00 CEST | Press release

SATO Corporation Press release 16 May 2022 at 9:00 am In February 2022, Vantaa Energy and SATO signed an energy partnership agreement that aims to support the achievement of SATO’s carbon neutrality target by 2030. Vantaa Energy leads the way in climate-friendly energy production and enables smooth everyday life for its customers by constantly developing climate-friendly energy services throughout the property lifecycle. SATO is one of Finland’s largest rental housing providers and makes carefree and sustainable rental housing available for its customers. The purpose of the cooperation between Vantaa Energy and SATO is to together promote and develop carbon-neutral energy solutions for the heating and cooling of buildings as well as new innovative ways to reduce energy consumption so that SATO will reach its targets in line with its strategy. Improving the energy efficiency of properties cuts heating costs and is one of the most important actions taken by SATO to curb climate change an